Внесуставные проявления ревматоидного артрита
https://doi.org/10.14412/1995-4484-2018-356-362
Аннотация
Ревматоидный артрит (РА) – иммуновоспалительное (аутоиммунное) ревматическое заболевание неизвестной этиологии, характеризующееся хроническим эрозивным артритом и системным поражением внутренних органов, приводящее к ранней инвалидности и сокращению жизни больных. Для постановки диагноза в настоящее время рекомендуется применение классификационных критериев РА (ACR/EULAR, 2010), согласно которым при клиническом исследовании необходимо выявить хотя бы один припухший сустав, т. е. наличие артрита; очевидно, поэтому проблема внесуставных проявлений РА остается в тени.
Об авторе
Ю. В. Муравьев
ФГБУ «Научно-исследовательский институт ревматологии им. В.А. Насоновой»
Россия
115522, Москва, Каширское шоссе, 34А
Россия
115522, Москва, Каширское шоссе, 34А
Список литературы
1. Тареев ЕМ. К учению о так называемом неспецифическом инфекционном артрите. Советская медицина. 1953;(6):15-21 [Tareev EM. To the doctrine of the so-called nonspecific infectious arthritis. Sovetskaya Meditsina. 1953;(6):15-21 (In Russ.)].
2. Тареев ЕМ. Висцеральные поражения при системных васкулитах и ревматоидном артрите. Советская медицина. 1956;(5):10-8 [Tareev EM. Visceral lesions in systemic vasculitis and rheumatoid arthritis. Sovetskaya Meditsina. 1956;(5):10-8 (In Russ.)].
3. Астапенко МГ, Пихлак ЭГ. Болезни суставов. Москва: Медицина; 1966. С. 99-116 [Astapenko MG, Pikhlak EG. Bolezni sustavov [Diseases of the joints]. Moscow: Meditsina; 1966. P. 99-116 (In Russ.)].
4. Насонов ЕЛ, редактор. Клинические рекомендации. Ревматология. Москва: ГЭОТАР-Медиа; 2005. 288 с. [Nasonov EL, editor. Klinicheskie rekomendatsii. Revmatologiya [Clinical recommendations. Rheumatology]. Moscow: GEOTARMedia; 2005. 288 p. (In Russ.)].
5. Каратеев ДЕ, Олюнин ЮА. О классификации ревматоидного артрита. Научно-практическая ревматология. 2008;46(1):5-16 [Karateev DE, Olunin YuA. About classification of rheumatoid arthritis. Nauchno-Prakticheskaya Revmatologiya = Rheumatology Science and Practice. 2008;46(1):5-16 (In Russ.)]. doi: 10.14412/1995-4484-2008-848
6. Насонов ЕЛ, редактор. Российские клинические рекомендации. Ревматология. Москва: ГЭОТАР-Медиа; 2017. 464 с. [Nasonov EL, editor. Rossiyskie klinicheskie rekomendatsii. Revmatologiya [Russian clinical guidelines. Rheumatology]. Moscow: GEOTAR-Media; 2017. 464 p. (In Russ.)].
7. Turesson C, O’Fallon WM, Crowson CS, Matteson EL. Occurrence of extra-articular disease manifestations is associated with excess mortality in a community based cohort of patients with rheumatoid arthritis. J Rheumatol. 2002;29:62-7.
8. Turesson C, Jacobsson L, Bergström U. Extra-articular rheumatoid arthritis: prevalence and mortality. Rheumatology (Oxford). 1999;38(7):668-74. doi: 10.1093/rheumatology/38.7.668
9. Das S, Padhan P. An Overview of the Extraarticular Involvement in Rheumatoid Arthritis and its Management. J Pharmacol Pharmacother. 2017;8(3):81-6.
10. Prete M, Racanelli V, Digiglio L, et al. Extra-articular manifestations of rheumatoid arthritis: An update. Autoimmun Rev. 2011;11(2):123-31. doi: 10.1016/j.autrev.2011.09.001
11. Turesson C, McClelland RL, Christianson TJ, Matteson EL. No decrease over time in the incidence of vasculitis or other extraarticular manifestations in rheumatoid arthritis: Results from a community-based study. Arthritis Rheum. 2004;50:3729-31. doi: 10.1002/art.20590
12. Bartels C, Bell C, Rosenthal A, et al. Decline in rheumatoid vasculitis prevalence among US veterans: A retrospective cross-sectional study. Arthritis Rheum. 2009;60:2553-7. doi: 10.1002/art.24775
13. Бестаев ДВ, Каратеев ДЕ, Насонов ЕЛ. Системные проявления ревматоидного артрита. Научно-практическая ревматология. 2013;51(1):76-80 [Bestaev DV, Karateev DE, Nasonov EL. Systemic manifestations of rheumatoid arthritis. Nauchno-Prakticheskaya Revmatologiya = Rheumatology Science and Practice. 2013;51(1):76-80 (In Russ.)]. doi: 10.14412/1995- 4484-2013-1206
14. Cronstein BN. Interleukin-6 – A key mediator of systemic and local symptoms in rheumatoid arthritis. Bull NYU Hosp Jt Dis. 2007;65(Suppl 1):S11-5.
15. Voskuyl AE, Zwinderman AH, Westedt ML, et al. Factors associated with the development of vasculitis in rheumatoid arthritis: Results of a case-control study. Ann Rheum Dis. 1996;55:190-2. doi: 10.1136/ard.55.3.190
16. Struthers GR, Scott DL, Delamere JP, et al. Smoking and rheumatoid vasculitis. Rheumatol Int. 1981;1:145-6. doi: 10.1007/BF00541260
17. Turesson C, Jacobsson L, Sturfelt G, et al. Rheumatoid factor and antibodies to cyclic citrullinated peptides are associated with severe extra-articular manifestations in rheumatoid arthritis. Ann Rheum Dis. 2006;66:59-64. doi: 10.1136/ard.2006.054445
18. Rojas-Villarraga A, Diaz FJ, Calvo-Paramo E, et al. Familial disease, the HLA-DRB1 shared epitope and anti-CCP antibodies influence time at appearance of substantial joint damage in rheumatoid arthritis. J Autoimmun. 2009;32:64-9. doi: 10.1016/j.jaut.2008.11.004
19. Bergström U, Book C, Lindroth Y, et al. Lower disease activity and disability in Swedish patients with rheumatoid arthritis in 1995 compared with 1978. Scand J Rheumatol. 1999;28:160-5. doi: 10.1080/03009749950154239
20. Watts RA, Scott DG .Vasculitis and inflammatory arthritis. Best Pract Res Clin Rheumatol. 2016;30(5):916-31. doi: 10.1016/j.berh.2016.10.008
21. Cojocaru M, Cojocaru IM, Silosi I, et al. Extra-articular manifestations in rheumatoid arthritis. Maedica (Buchar) 2010;5:286-91.
22. Saraux A, Allain J, Guedes C, et al. Raynaud’s phenomenon in rheumatoid arthritis. Br J Rheumatol. 1996;35:752-4. doi: 10.1093/rheumatology/35.8.752
23. Bongartz T, Nannini C, Medina-Velasquez YF, et al. Incidence and mortality of interstitial lung disease in rheumatoid arthritis: A population-based study. Arthritis Rheum. 2010;62:1583-91. doi: 10.1002/art.27405
24. Prete M, Racanelli V, Digiglio L, et al. Extra-articular manifestations of rheumatoid arthritis: An update. Autoimmun Rev. 2011;11:123-31. doi: 10.1016/j.autrev.2011.09.001
25. Olson AL, Swigris JJ, Sprunger DB, et al. Rheumatoid arthritisinterstitial lung disease-associated mortality. Am J Respir Crit Care Med. 2011;183:372-8. doi: 10.1164/rccm.201004-0622OC
26. Lee HK, Kim DS, Yoo B, et al. Histopathologic pattern and clinical features of rheumatoid arthritis-associated interstitial lung disease. Chest. 2005;127:2019-27. doi: 10.1378/chest.127.6.2019
27. Kelly CA, Saravanan V, Nisar M, et al. Rheumatoid arthritis-related interstitial lung disease: Associations, prognostic factors and physiological and radiological characteristics – A large multicentre UK study. Rheumatology (Oxford). 2014;53:1676-82. doi: 10.1093/rheumatology/keu165
28. Mori S. Management of rheumatoid arthritis patients with interstitial lung disease: Safety of biological antirheumatic drugs and assessment of pulmonary fibrosis. Clin Med Insights Circ Respir Pulm Med. 2015;9:41-9. doi: 10.4137/CCRPM.S23288
29. Vij R, Strek ME. Diagnosis and treatment of connective tissue disease-associated interstitial lung disease. Chest. 2013;143:814-24. doi: 10.1378/chest.12-0741
30. De Lauretis A, Veeraraghavan S, Renzoni E. Review series: Aspects of interstitial lung disease: Connective tissue disease-associated interstitial lung disease: How does it differ from IPF? How should the clinical approach differ? Chron Respir Dis. 2011;8:53- 82. doi: 10.1177/1479972310393758
31. Liote H. Pulmonary manifestation of rheumatoid arthritis. Rev Mal Respir. 2008;25:973-88.
32. Solomon DH, Karlson EW, Rimm EB, et al. Cardiovascular morbidity and mortality in women diagnosed with rheumatoid arthritis. Circulation. 2003;107:1303-7. doi: 10.1161/01.CIR.0000054612.26458.B2
33. Ortega-Hernandez OD, Pineda-Tamayo R, Pardo AL, et al. Cardiovascular disease is associated with extra-articular manifestations in patients with rheumatoid arthritis. Clin Rheumatol. 2009;28:767-75. doi: 10.1007/s10067-009-1145-8
34. Voskuyl AE. The heart and cardiovascular manifestations in rheumatoid arthritis. Rheumatology (Oxford). 2006;45(Suppl 4):iv4-7. doi: 10.1093/rheumatology/kel313
35. Kitas G, Banks MJ, Bacon PA. Cardiac involvement in rheumatoid disease. Clin Med (Lond). 2001;1:18-21. doi: 10.7861/clinmedicine.1-1-18
36. Das S, Mohanty M, Padhan P. Outcome of rheumatoid arthritis following adjunct statin therapy. Indian J Pharmacol. 2015;47:605- 9. doi: 10.4103/0253-7613.169585
37. Turesson C, Jarenros A, Jacobsson L. Increased incidence of cardiovascular disease in patients with rheumatoid arthritis: Results from a community based study. Ann Rheum Dis. 2004;63:952-5. doi: 10.1136/ard.2003.018101
38. Agarwal V, Singh R, Wiclaf F, et al. A clinical, electrophysiological, and pathological study of neuropathy in rheumatoid arthritis. Clin Rheumatol. 2008;27:841-4. doi: 10.1007/s10067-007- 0804-x
39. Muramatsu K, Tanaka H, Taguchi T. Peripheral neuropathies of the forearm and hand in rheumatoid arthritis: Diagnosis and options for treatment. Rheumatol Int. 2008;28:951-7. doi: 10.1007/s00296-008-0630-8
40. Ito H, Neo M, Sakamoto T, et al. Subaxial subluxation after atlantoaxial transarticular screw fixation in rheumatoid patients. Eur Spine J. 2009;18:869-76. doi: 10.1007/s00586- 009-0945-5
41. Schett G, Hayer S, Zwerina J, et al. Mechanisms of disease: The link between RANKL and arthritic bone disease. Nat Clin Pract Rheumatol. 2005;1:47-54. doi: 10.1038/ncprheum0036
42. Mielants H, van den Bosch F. Extra-articular manifestations. Clin Exp Rheumatol. 2009;27:S56-61.
43. Korpela M, Mustonen J, Teppo AM, et al. Mesangial glomerulonephritis as an extra-articular manifestation of rheumatoid arthritis. Br J Rheumatol. 1997;36:1189-95. doi: 10.1093/rheumatology/36.11.1189
44. Balint GP, Balint PV. Felty’s syndrome. Best Pract Res Clin Rheumatol. 2004;18:631-45. doi: 10.1016/j.berh.2004.05.002
45. Baecklund E, Iliadou A, Askling J, et al. Association of chronic inflammation, not its treatment, with increased lymphoma risk in rheumatoid arthritis. Arthritis Rheum. 2006;54:692-701. doi: 10.1002/art.21675
46. Bowman SJ. Hematological manifestations of rheumatoid arthritis. Scand J Rheumatol. 2002;31:251-9. doi: 10.1080/030097402760375124
47. Felty AR. Chronic arthritis in the adult associated with splenomegaly and leucopenia. Bull Johns Hopkins Hospital. 1924;35:16-20.
48. Hanrahan EM, Miller SR. Effect of splenectomy in Felty’s syndrome. JAMA. 1932;99:1247-9. doi: 10.1001/jama.1932.02740670035010
49. Goldberg J, Pinals RS. Felty syndrome. Semin Arthritis Rheum. 1980;10:52-65. doi: 10.1016/0049-0172(80)90014-1
50. Barnes CG, Turnbull AL, Vernon-Roberts B. Felty’s syndrome. A clinical and pathological survey of 21 patients and their response to treatment. Ann Rheum Dis. 1971;30:359-74. doi: 10.1136/ard.30.4.359
51. Sienknecht CW, Urowitz MB, Pruzanski W, Stein HB. Felty’s syndrome. Clinical and serological analysis of 34 cases. Ann Rheum Dis. 1977;36:500-7. doi: 10.1136/ard.36.6.500
52. Campion G, Maddison PJ, Goulding N, et al. The Felty syndrome: a case-matched study of clinical manifestations and outcome, serologic features, and immunogenetic associations. Medicine. 1990;69:69-80. doi: 10.1097/00005792-199069020-00001
53. Denko CW, Zumpft CW. Chronic arthritis with splenomegaly and leukopenia. Arthritis Rheum. 1962;5:478-91. doi: 10.1002/art.1780050505
54. Ruderman M, Miller LM, Pinals RS. Clinical and serological observations on 27 patients with Felty’s syndrome. Arthritis Rheum. 1968;11:377-84. doi: 10.1002/art.1780110302
55. Rosenstein ED, Kramer N. Felty’s and pseudo-Felty’s syndromes. Semin Arthritis Rheum. 1991;21(3):129-42. doi: 10.1016/0049- 0172(91)90002-H
56. Breedveld FC, Fibbe WE, Cats A. Neutropenia and infections in Felty’s syndrome. Brit J Rheumatol. 1988;27:191-7. doi: 10.1093/rheumatology/27.3.191
57. Cornwell GG, Zacharski LR. Neutropenia, elevated rheumatoid factor, splenomegaly, and absence of rheumatoid arthritis. Ann Intern Med. 1974;80:555-6. doi: 10.7326/0003-4819-80-4-555
58. Bradley JD, Pinals RS. Felty’s syndrome presenting without arthritis. Clin Exp Rheumatol. 1983;1:257-9.
59. Armstrong RD. Fernandes L, Gibson T, et al. Felty’s syndrome presenting without arthritis. Br Med J. 1983;287:1620. doi: 10.1136/bmj.287.6405.1620
60. Moore RA, Brunner CM, Sandusky WR, Leavell BS. Felty's syndrome: long-term follow-up after splenectomy. Ann Intern Med. 1971;75(3):381-5. doi: 10.7326/0003-4819-75-3-381
61. Bucknall RC, Davis P, Bacon PA, Jones JV. Neutropenia in rheumatoid arthritis: studies on possible contributing factors. Ann Rheum Dis. 1982;41:242-7. doi: 10.1136/ard.41.3.242
62. Thorne C, Urowitz MB. Long-term outcome in Felty’s syndrome. Ann Rheum Dis. 1982;41:486-9. doi: 10.1136/ard.41.5.486
63. Turesson C. Extra-articular rheumatoid arthritis. Curr Opin Rheumatol. 2013;25(3):360-6. doi: 10.1097/BOR.0b013e32835f693f
64. Watts RA, Ntatsaki E. Refractory rheumatoid vasculitis – a therapeutic dilemma. Oxf Med Case Reports. 2016;2016(11):omw081. doi: 10.1093/omcr/omw081
65. Ntatsaki E, Mooney J, Scott DGI, Watts RA. Systemic rheumatoid vasculitis in the era of modern immunosuppressive therapy. Rheumatology (Oxford) 2014;53:145-52. doi: 10.1093/rheumatology/ket326
66. Theander L, Nyhä ll-Wahlin BM, Nilsson JA, et al. Severe Extraarticular Manifestations in a Community-based Cohort of Patients with Rheumatoid Arthritis: Risk Factors and Incidence in Relation to Treatment with Tumor Necrosis Factor Inhibitors. J Rheumatol. 2017;44(7):981-7. doi: 10.3899/jrheum.161103
67. Genta MS, Genta RM, Gabay C. Systemic rheumatoid vasculitis: a review. Semin Arthritis Rheum. 2006;36:88-98. doi: 10.1016/j.semarthrit.2006.04.006
68. Armstrong DJ, McCarron MT, Wright GD. Successful treatment of rheumatoid vasculitis-associated foot-drop with infliximab. J Rheumatol. 2005;32:759-60.
69. Garcia-Porrua C, Gonzalez-Gay MA, Quevedo V. Should antitumor necrosis factor-alpha be the first therapy for rheumatoid vasculitis? J Rheumatol. 2006;33:433-4.
70. Puechal X, Miceli-Richard C, Mejjad O, et al. Anti-tumour necrosis factor treatment in patients with refractory systemic vasculitis associated with rheumatoid arthritis. Ann Rheum Dis. 2008;67:880-4. doi: 10.1136/ard.2007.081679
71. Hellmann M, Jung N, Owczarczyk K, et al. Successful treatment of rheumatoid vasculitis-associated cutaneous ulcers using rituximab in two patients with rheumatoid arthritis. Rheumatology (Oxford). 2008;47:929-30. doi: 10.1093/rheumatology/ken129
72. Garcia-Carrasco M, Jimenez-Hernandez M, Escarcega RO, et al. Treatment of Raynaud’s phenomenon. Autoimmun Rev. 2008;8:62- 8. doi: 10.1016/j.autrev.2008.07.002
73. Turesson C, Matteson EL. Management of extra-articular disease manifestations in rheumatoid arthritis. Curr Opin Rheumatol. 2004;16:206-11. doi: 10.1097/00002281-200405000-00007
74. Turiel M, Sitia S, Atzeni F, et al. The heart in rheumatoid arthritis. Autoimmun Rev. 2010;9:414-8. doi: 10.1016/j.autrev.2009.11.002
75. Mielants H, van den Bosch F. Extra-articular manifestations. Clin Exp Rheumatol. 2009;27:S56-61.
76. Mrabet D, Meddeb N, Ajlani H, et al. Cerebral vasculitis in a patient with rheumatoid arthritis. Joint Bone Spine. 2007;74:201-4. doi: 10.1016/j.jbspin.2006.08.004
77. Atchia II, Kidd CE, Bell RW. Rheumatoid arthritis-associated necrotizing scleritis and peripheral ulcerative keratitis treated successfully with infliximab. J Clin Rheumatol. 2006;12:291-3. doi: 10.1097/01.rhu.0000249766.24780.95
78. Restrepo JP, Molina MP. Successful treatment of severe nodular scleritis with adalimumab. Clin Rheumatol. 2010;29:559-61. doi: 10.1007/s10067-009-1368-8
79. Iaccheri B, Androudi S, Bocci EB, et al. Rituximab treatment for persistent scleritis associated with rheumatoid arthritis. Ocul Immunol Inflamm. 2010;18:223-5. doi: 10.3109/09273941003739928
80. Wassenberg S, Herborn G, Rau R. Methotrexate treatment in Felty's syndrome. Br J Rheumatol. 1998;37:908-11. doi: 10.1093/rheumatology/37.8.908
81. Lekharaju V, Chattopadhyay C. Efficacy of rituximab in Felty's syndrome. Ann Rheum Dis. 2008;67:1352. doi: 10.1136/ard.2007.078915
82. Nishida S, Hagihara K, Shima Y, et al. Rapid improvement of AA amyloidosis with humanised anti-interleukin 6 receptor antibody treatment. Ann Rheum Dis. 2009;68:1235-6. doi: 10.1136/ard.2008.099267
83. Inoue D, Arima H, Kawanami C, et al. Excellent therapeutic effect of tocilizumab on intestinal amyloid a deposition secondary to active rheumatoid arthritis. Clin Rheumatol. 2010;29:1195-7. doi: 10.1007/s10067-010-1422-6
Рецензия
Для цитирования:
Муравьев Ю.В. Внесуставные проявления ревматоидного артрита. Научно-практическая ревматология. 2018;56(3):356-362. https://doi.org/10.14412/1995-4484-2018-356-362
For citation:
Muravyev Yu.V. EXTRA-ARTICULAR MANIFESTATIONS OF RHEUMATOID ARTHRITIS. Rheumatology Science and Practice. 2018;56(3):356-362. (In Russ.) https://doi.org/10.14412/1995-4484-2018-356-362
Просмотров: 2528
Послать статью по эл. почте 